<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003972</url>
  </required_header>
  <id_info>
    <org_study_id>1316.00</org_study_id>
    <secondary_id>FHCRC-1316.00</secondary_id>
    <secondary_id>PSOC-1604</secondary_id>
    <secondary_id>NCI-G99-1552</secondary_id>
    <secondary_id>CDR0000067175</secondary_id>
    <nct_id>NCT00003972</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer</brief_title>
  <official_title>A Phase III Study of High-Dose Chemotherapy Using Busulfan, Melphalan and Thiotepa Versus Cyclophosphamide,Thiotepa, Carboplatin Followed by Autologous Stem Cell Transplantation in Patients With High-Risk Primary Stage II or III (Non-Inflammatory) Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It&#xD;
      is not yet known which regimen of combination chemotherapy is more effective for breast&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of&#xD;
      combination chemotherapy followed by peripheral stem cell transplantation in treating&#xD;
      patients who have stage II or stage IIIA breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare early mortality, survival, and disease free survival in patients with&#xD;
      node positive stage II or IIIA breast cancer treated with busulfan, melphalan, and thiotepa&#xD;
      versus cyclophosphamide, thiotepa, and carboplatin followed by autologous peripheral blood&#xD;
      stem cell transplantation. II. Compare the toxicity of these 2 regimens in this patient&#xD;
      population.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to stage of disease&#xD;
      (stage II vs stage IIIA), lymph node status (at least 10 positive nodes vs less than 10&#xD;
      positive nodes), and hormone receptor status (estrogen receptor positive or progesterone&#xD;
      receptor positive vs estrogen receptor negative or progesterone receptor negative). All&#xD;
      patients initially receive mobilization chemotherapy with cyclophosphamide IV over 1-2 hours&#xD;
      on day 1 and paclitaxel IV over 4 hours on day 2. Beginning on day 4, patients receive&#xD;
      filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously each day until the final day of&#xD;
      leukapheresis. When blood counts recover, peripheral blood stem cells (PBSC) are harvested.&#xD;
      Patients are randomized to 1 of 2 high dose chemotherapy regimens 28-45 days after the last&#xD;
      dose of mobilization chemotherapy. Arm I: Patients receive oral busulfan every 6 hours on&#xD;
      days -8 to -6, melphalan IV over 30-60 minutes on days -5 and -4, and thiotepa IV over 2&#xD;
      hours on days -3 and -2. PBSC are reinfused on day 0. Arm II: Patients receive&#xD;
      cyclophosphamide, thiotepa, and carboplatin by continuous IV infusion over 24 hours on days&#xD;
      -7, to -4. PBSC are reinfused on day 0. Beginning 4-6 weeks after the last dose of&#xD;
      chemotherapy, patients in both arms receive local radiotherapy 5 days each week for 5 weeks.&#xD;
      Patients also receive oral tamoxifen (or equivalent antiestrogen therapy) daily for 5 years&#xD;
      if they are estrogen or progesterone receptor positive, postmenopausal, or age 50 and over&#xD;
      and perimenopausal. Patients are followed every 3 months for 2 years and then every 6 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 280 patients (140 per treatment arm) will be accrued for this&#xD;
      study over 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven stage II breast cancer with 1 of the&#xD;
        following: Estrogen receptor negative with at least 4 positive nodes OR Estrogen receptor&#xD;
        positive with at least 6 positive nodes OR Histologically proven stage IIIA breast cancer&#xD;
        Must have already received 4-7 courses of conventional chemotherapy with a doxorubicin&#xD;
        based regimen (which may include paclitaxel or docetaxel) No greater than 60 days since&#xD;
        induction chemotherapy Prior definitive surgical treatment of primary lesion (modified&#xD;
        radical mastectomy or breast conserving procedure plus axillary node dissection) Margins&#xD;
        free of tumor Hormone receptor status: Estrogen and progesterone receptor status known&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 to 65 Menopausal status: Not specified Performance status:&#xD;
        Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: Not specified Hepatic:&#xD;
        Bilirubin no greater than 2.0 mg/dL SGOT or SGPT no greater than 2 times normal Renal:&#xD;
        Creatinine no greater than 2.0 mg/dL OR Creatinine clearance at least 60 mL/min&#xD;
        Cardiovascular: Left ventricular ejection fraction at least 50% if any of the following:&#xD;
        Symptoms of congestive heart failure Abnormal cardiac exam Prior doxorubicin dose greater&#xD;
        than 400 mg/m2 Pulmonary: No significant pulmonary disease (DLCO less than 60% predicted)&#xD;
        Other: Not pregnant Negative pregnancy test HIV negative No significant active infection No&#xD;
        other severe disease that would severely limit life expectancy No other malignancy within&#xD;
        past 5 years unless: Chance of survival for greater than 5 years is 90% AND Treated with&#xD;
        surgery only (no chemotherapy or radiotherapy)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease&#xD;
        Characteristics No greater than 1 prior chemotherapy regimen (no greater than 7 prior&#xD;
        courses) Endocrine therapy: No concurrent tamoxifen Radiotherapy: Not specified Surgery:&#xD;
        See Disease Characteristics Other: No other concurrent experimental agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William I. Bensinger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2004</study_first_posted>
  <last_update_submitted>March 31, 2010</last_update_submitted>
  <last_update_submitted_qc>March 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

